NCT03283696View on ClinicalTrials.gov

A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 18, 2017

Primary Completion Date

April 29, 2019

Study Completion Date

August 25, 2019

Conditions

Soft Tissue Sarcoma

Interventions

DRUG

Olaratumab

Administered IV

DRUG

Doxorubicin

Administered IV

DRUG

Ifosfamide

Administered IV

DRUG

Mesna

Administered per standard of care

Trial Locations (6)

13125

HELIOS Klinikum Berlin-Buch, Berlin

20133

Istituto Nazionale dei Tumori, Milan

33136

University of Miami School of Medicine, Miami

45122

Universitätsklinikum Essen, Essen

77030

University of Texas MD Anderson Cancer Center, Houston

95123

Università degli Studi di Catania - Azienda Policlinico, Catania

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT03283696 - A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma | Biotech Hunter | Biotech Hunter